Novel biomarkers of cardiovascular disease: Applications in clinical practice

References

• World Health Organization. Fact sheet No 317: Cardiovascular diseases. [cited 2018 May 15]. Available from: http://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
   Google Scholar
• Savji N, Rockman CB, Skolnick AH, et al. Association between advanced age and vascular disease in different arterial territories: a population database of over 3.6 million subjects. J Am Coll Cardiol. 2013;61:1736–1743.
   PubMed Web of Science ®Google Scholar
• Kannel WB, D'Agostino RB, Silbershatz H, et al. Profile for estimating risk of heart failure. Arch Intern Med. 1999;159:1197–1204.
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497.
   PubMed Web of Science ®Google Scholar
• Schnabel RB, Sullivan LM, Levy D, et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet. 2009;373:739–745.
   PubMed Web of Science ®Google Scholar
• D'Agostino RB, Sr., Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743–753.
   PubMed Web of Science ®Google Scholar
• Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S49–S73.
   PubMed Web of Science ®Google Scholar
• Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003.
   PubMed Web of Science ®Google Scholar
• Anderson TJ, Gregoire J, Pearson GJ, et al. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2016;32:1263–1282.
   PubMed Web of Science ®Google Scholar
• Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.
   PubMed Web of Science ®Google Scholar
• Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation. 2007;115:949–952.
   PubMed Web of Science ®Google Scholar
• Tripepi G, Jager KJ, Dekker FW, et al. Statistical methods for the assessment of prognostic biomarkers (Part I): discrimination. Nephrol Dial Transplant. 2010;25:1399–1401.
   PubMed Web of Science ®Google Scholar
• Tripepi G, Jager KJ, Dekker FW, et al. Statistical methods for the assessment of prognostic biomarkers(part II): calibration and re-classification. Nephrol Dial Transplant. 2010;25:1402–1405.
   PubMed Web of Science ®Google Scholar
• Pencina MJ, D'Agostino RB, Sr., D'Agostino RB Jr, et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157–172. discussion 207-12.
   PubMed Web of Science ®Google Scholar
• Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29–36.
   PubMed Web of Science ®Google Scholar
• Uno H, Cai T, Pencina MJ, et al. On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med. 2011;30:1105–1117.
   PubMed Web of Science ®Google Scholar
• Kramer AA, Zimmerman JE. Assessing the calibration of mortality benchmarks in critical care: the Hosmer-Lemeshow test revisited. Crit Care Med. 2007;35:2052–2056.
   PubMed Web of Science ®Google Scholar
• Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21:128–138.
   PubMed Web of Science ®Google Scholar
• Pencina MJ, D'Agostino RB, Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30:11–21.
   PubMed Web of Science ®Google Scholar
• Pencina MJ, D'Agostino RB, Pencina KM, et al. Interpreting incremental value of markers added to risk prediction models. Am J Epidemiol. 2012;176:473–481.
   PubMed Web of Science ®Google Scholar
• Pepe MS, Kerr KF, Longton G, et al. Testing for improvement in prediction model performance. Stat Med. 2013;32:1467–1482.
   PubMed Web of Science ®Google Scholar
• Kerr KF, Wang Z, Janes H, et al. Net reclassification indices for evaluating risk prediction instruments: a critical review. Epidemiology. 2014;25:114–121.
   PubMed Web of Science ®Google Scholar
• Keller T, Zeller T, Peetz D, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med. 2009;361:868–877.
   PubMed Web of Science ®Google Scholar
• Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction. Eur Heart J. 2018;2018:ehy462–ehy462.
   Google Scholar
• Kvisvik B, Morkrid L, Rosjo H, et al. High-sensitivity troponin T vs I in acute coronary syndrome: prediction of significant coronary lesions and long-term prognosis. Clin Chem. 2017;63:552–562.
   PubMed Web of Science ®Google Scholar
• Samman Tahhan A, Sandesara P, Hayek SS, et al. High-sensitivity troponin I levels and coronary artery disease severity, progression, and long-term outcomes. J Am Heart Assoc. 2018;7.
   Web of Science ®Google Scholar
• deFilippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA. 2010;304:2494–2502.
   PubMed Web of Science ®Google Scholar
• Saunders JT, Nambi V, de Lemos JA, et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation. 2011;123:1367–1376.
   PubMed Web of Science ®Google Scholar
• Zeller T, Tunstall-Pedoe H, Saarela O, et al. High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort. Eur Heart J. 2014;35:271–281.
   PubMed Web of Science ®Google Scholar
• deFilippi CR, de Lemos JA, Tkaczuk AT, et al. Physical activity, change in biomarkers of myocardial stress and injury, and subsequent heart failure risk in older adults. J Am Coll Cardiol. 2012;60:2539–2547.
   PubMed Web of Science ®Google Scholar
• Ndumele CE, Coresh J, Lazo M, et al. Obesity, subclinical myocardial injury, and incident heart failure. JACC Heart Fail. 2014;2:600–607.
   PubMed Web of Science ®Google Scholar
• McEvoy JW, Chen Y, Ndumele CE, et al. Six-year change in high-sensitivity cardiac troponin T and risk of subsequent coronary heart disease, heart failure, and death. JAMA Cardiol. 2016;1:519–528.
   PubMed Web of Science ®Google Scholar
• Evans JDW, Dobbin SJH, Pettit SJ, et al. High-sensitivity cardiac troponin and new-onset heart failure: a systematic review and meta-analysis of 67,063 patients with 4,165 incident heart failure events. JACC Heart Fail. 2018;6:187–197.
   PubMed Web of Science ®Google Scholar
• Rienstra M, Yin X, Larson MG, et al. Relation between soluble ST2, growth differentiation factor-15, and high-sensitivity troponin I and incident atrial fibrillation. Am Heart J. 2014;167:109–115 e2.
   PubMed Web of Science ®Google Scholar
• Filion KB, Agarwal SK, Ballantyne CM, et al. High-sensitivity cardiac troponin T and the risk of incident atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2015;169: 31–38 e3.
   PubMed Web of Science ®Google Scholar
• Hijazi Z, Siegbahn A, Andersson U, et al. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014;129:625–634.
   PubMed Web of Science ®Google Scholar
• Hijazi Z, Wallentin L, Siegbahn A, et al. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. J Am Coll Cardiol. 2014;63:52–61.
   PubMed Web of Science ®Google Scholar
• Shah AS, Anand A, Sandoval Y, et al. High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study. Lancet. 2015;386:2481–2488.
   PubMed Web of Science ®Google Scholar
• Roos A, Bandstein N, Lundback M, et al. Stable high-sensitivity cardiac troponin T levels and outcomes in patients with chest pain. J Am Coll Cardiol. 2017;70:2226–2236.
   PubMed Web of Science ®Google Scholar
• Omland T, de Lemos JA, Sabatine MS, et al. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med. 2009;361:2538–2547.
   PubMed Web of Science ®Google Scholar
• Vavik V, Pedersen EKR, Svingen GFT, et al. Usefulness of higher levels of cardiac troponin T in patients with stable Angina Pectoris to predict risk of acute myocardial infarction. Am J Cardiol. 2018;122:1142–1147.
   PubMed Web of Science ®Google Scholar
• McQueen MJ, Kavsak PA, Xu L, et al. Predicting myocardial infarction and other serious cardiac outcomes using high-sensitivity cardiac troponin T in a high-risk stable population. Clin Biochem. 2013;46:5–9.
   PubMed Web of Science ®Google Scholar
• Horwich TB, Patel J, MacLellan WR, et al. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation. 2003;108:833–838.
   PubMed Web of Science ®Google Scholar
• Latini R, Masson S, Anand IS, et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation. 2007;116:1242–1249.
   PubMed Web of Science ®Google Scholar
• Peacock WF, De Marco T, Fonarow GC, et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med. 2008;358:2117–2126.
   PubMed Web of Science ®Google Scholar
• Ammann P, Maggiorini M, Bertel O, et al. Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes. J Am Coll Cardiol. 2003;41:2004–2009.
   PubMed Web of Science ®Google Scholar
• Mehta NJ, Khan IA, Gupta V, et al. Cardiac troponin I predicts myocardial dysfunction and adverse outcome in septic shock. Int J Cardiol. 2004;95:13–17.
   PubMed Web of Science ®Google Scholar
• John J, Woodward DB, Wang Y, et al. Troponin-I as a prognosticator of mortality in severe sepsis patients. J Crit Care. 2010;25:270–275.
   PubMed Web of Science ®Google Scholar
• Vasile VC, Chai HS, Abdeldayem D, et al. Elevated cardiac troponin T levels in critically ill patients with sepsis. Am J Med. 2013;126:1114–1121.
   PubMed Web of Science ®Google Scholar
• McCann CJ, Glover BM, Menown IB, et al. Novel biomarkers in early diagnosis of acute myocardial infarction compared with cardiac troponin T. Eur Heart J. 2008;29:2843–2850.
   PubMed Web of Science ®Google Scholar
• Ishii J, Ozaki Y, Lu J, et al. Prognostic value of serum concentration of heart-type fatty acid-binding protein relative to cardiac troponin T on admission in the early hours of acute coronary syndrome. Clin Chem. 2005;51:1397–1404.
   PubMed Web of Science ®Google Scholar
• O'Donoghue M, de Lemos JA, Morrow DA, et al. Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. Circulation. 2006;114:550–557.
   PubMed Web of Science ®Google Scholar
• Viswanathan K, Kilcullen N, Morrell C, et al. Heart-type fatty acid-binding protein predicts long-term mortality and re-infarction in consecutive patients with suspected acute coronary syndrome who are troponin-negative. J Am Coll Cardiol. 2010;55:2590–2598.
   PubMed Web of Science ®Google Scholar
• Arimoto T, Takeishi Y, Shiga R, et al. Prognostic value of elevated circulating heart-type fatty acid binding protein in patients with congestive heart failure. J Card Fail. 2005;11:56–60.
   PubMed Web of Science ®Google Scholar
• Niizeki T, Takeishi Y, Arimoto T, et al. Persistently increased serum concentration of heart-type fatty acid-binding protein predicts adverse clinical outcomes in patients with chronic heart failure. Circ J. 2008;72:109–114.
   PubMed Web of Science ®Google Scholar
• Hoffmann U, Espeter F, Weiss C, et al. Ischemic biomarker heart-type fatty acid binding protein (hFABP) in acute heart failure – diagnostic and prognostic insights compared to NT-proBNP and troponin I. BMC Cardiovasc Disord. 2015;15:50.
   PubMed Web of Science ®Google Scholar
• Kaier TE, Stengaard C, Marjot J, et al. Cardiac myosin-binding protein C as alternative to cardiac troponin T for the diagnosis of acute myocardial infarction in the very early phase. J Am Coll Cardiol. 2017;69:221.
   Google Scholar
• Tong CW, Dusio GF, Govindan S, et al. Usefulness of released cardiac myosin binding protein-C as a predictor of cardiovascular events. Am J Cardiol. 2017;120:1501–1507.
   PubMed Web of Science ®Google Scholar
• Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol. 2010;55:2062–2076.
   PubMed Web of Science ®Google Scholar
• Shah RV, Truong QA, Gaggin HK, et al. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J. 2012;33:2197–2205.
   PubMed Web of Science ®Google Scholar
• Khan SQ, Dhillon O, Kelly D, et al. Plasma N-terminal B-Type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol. 2008;51:1857–1864.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Morrow DA, de Lemos JA, et al. Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation. 2012;125:233–240.
   PubMed Web of Science ®Google Scholar
• Luers C, Sutcliffe A, Binder L, et al. NT-proANP and NT-proBNP as prognostic markers in patients with acute decompensated heart failure of different etiologies. Clin Biochem. 2013;46:1013–1019.
   PubMed Web of Science ®Google Scholar
• Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161–167.
   PubMed Web of Science ®Google Scholar
• Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350:655–663.
   PubMed Web of Science ®Google Scholar
• Omland T, Sabatine MS, Jablonski KA, et al. Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll Cardiol. 2007;50:205–214.
   PubMed Web of Science ®Google Scholar
• Patton KK, Ellinor PT, Heckbert SR, et al. N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study. Circulation. 2009;120:1768–1774.
   PubMed Web of Science ®Google Scholar
• Folsom AR, Nambi V, Bell EJ, et al. Troponin T, N-terminal pro-B-type natriuretic peptide, and incidence of stroke: the atherosclerosis risk in communities study. Stroke. 2013;44:961–967.
   PubMed Web of Science ®Google Scholar
• Omland T, Aakvaag A, Bonarjee VV, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation. 1996;93:1963–1969.
   PubMed Web of Science ®Google Scholar
• Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation. 1998;97:1921–1929.
   PubMed Web of Science ®Google Scholar
• Richards AM, Nicholls MG, Espiner EA, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation. 2003;107:2786–2792.
   PubMed Web of Science ®Google Scholar
• Kragelund C, Gronning B, Kober L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 2005;352:666–675.
   PubMed Web of Science ®Google Scholar
• Bibbins-Domingo K, Gupta R, Na B, et al. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA. 2007;297:169–176.
   PubMed Web of Science ®Google Scholar
• Hall C, Rouleau JL, Moye L, et al. N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. Circulation. 1994;89:1934–1942.
   PubMed Web of Science ®Google Scholar
• Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003;107:1278–1283.
   PubMed Web of Science ®Google Scholar
• Maisel A, Hollander JE, Guss D, et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol. 2004;44:1328–1333.
   PubMed Web of Science ®Google Scholar
• Doust JA, Pietrzak E, Dobson A, et al. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ. 2005;330:625.
   PubMed Web of Science ®Google Scholar
• Hijazi Z, Oldgren J, Andersson U, et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation. 2012;125:1605–1616.
   PubMed Web of Science ®Google Scholar
• Januzzi JL, Morss A, Tung R, et al. Natriuretic peptide testing for the evaluation of critically ill patients with shock in the intensive care unit: a prospective cohort study. Crit Care. 2006;10:R37.
   PubMed Web of Science ®Google Scholar
• Khan SQ, O’Brien RJ, Struck J, et al. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol. 2007;49:1525–1532.
   PubMed Web of Science ®Google Scholar
• Dhillon OS, Khan SQ, Narayan HK, et al. Prognostic value of mid-regional pro-adrenomedullin levels taken on admission and discharge in non-ST-elevation myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) II study. J Am Coll Cardiol. 2010;56:125–133.
   PubMed Web of Science ®Google Scholar
• Travaglino F, De Berardinis B, Magrini L, et al. Utility of Procalcitonin (PCT) and Mid regional pro-Adrenomedullin (MR-proADM) in risk stratification of critically ill febrile patients in Emergency Department (ED). A comparison with APACHE II score. BMC Infect Dis. 2012;12:184.
   PubMed Web of Science ®Google Scholar
• Reichlin T, Hochholzer W, Stelzig C, et al. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol. 2009;54:60–68.
   PubMed Web of Science ®Google Scholar
• Keller T, Tzikas S, Zeller T, et al. Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol. 2010;55:2096–2106.
   PubMed Web of Science ®Google Scholar
• Maisel A, Mueller C, Neath SX, et al. Copeptin helps in the early detection of patients with acute myocardial infarction: primary results of the CHOPIN trial (Copeptin Helps in the early detection of patients with acute myocardial INfarction). J Am Coll Cardiol. 2013;62:150–160.
   PubMed Web of Science ®Google Scholar
• Khan SQ, Dhillon OS, O'Brien RJ, et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation. 2007;115:2103–2110.
   PubMed Web of Science ®Google Scholar
• Stoiser B, Mortl D, Hulsmann M, et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest. 2006;36:771–778.
   PubMed Web of Science ®Google Scholar
• Neuhold S, Huelsmann M, Strunk G, et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol. 2008;52:266–272.
   PubMed Web of Science ®Google Scholar
• Voors AA, von Haehling S, Anker SD, et al. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J. 2009;30:1187–1194.
   PubMed Web of Science ®Google Scholar
• Katan M, Fluri F, Morgenthaler NG, et al. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol. 2009;66:799–808.
   PubMed Web of Science ®Google Scholar
• De Marchis GM, Katan M, Weck A, et al. Copeptin adds prognostic information after ischemic stroke: results from the CoRisk study. Neurology. 2013;80:1278–1286.
   PubMed Web of Science ®Google Scholar
• Tu WJ, Dong X, Zhao SJ, et al. Prognostic value of plasma neuroendocrine biomarkers in patients with acute ischaemic stroke. J Neuroendocrinol. 2013;25:771–778.
   PubMed Web of Science ®Google Scholar
• Struck J, Morgenthaler NG, Bergmann A, Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides. 2005;26:2500–2504.
   PubMed Web of Science ®Google Scholar
• Seligman R, Papassotiriou J, Morgenthaler NG, et al. Copeptin, a novel prognostic biomarker in ventilator-associated pneumonia. Crit Care. 2008;12:R11.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–843.
   PubMed Web of Science ®Google Scholar
• Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132–140.
   PubMed Web of Science ®Google Scholar
• Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003;107:1486–1491.
   PubMed Web of Science ®Google Scholar
• Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003;108:3006–3010.
   PubMed Web of Science ®Google Scholar
• Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol. 2007;50:2021–2028.
   PubMed Web of Science ®Google Scholar
• Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994;331:417–424.
   PubMed Web of Science ®Google Scholar
• Lindahl B, Toss H, Siegbahn A, et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med. 2000;343:1139–1147.
   PubMed Web of Science ®Google Scholar
• Chew DP, Bhatt DL, Robbins MA, et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation. 2001;104:992–997.
   PubMed Web of Science ®Google Scholar
• Park DW, Lee SW, Yun SC, et al. A point-of-care platelet function assay and C-reactive protein for prediction of major cardiovascular events after drug-eluting stent implantation. J Am Coll Cardiol. 2011;58:2630–2639.
   PubMed Web of Science ®Google Scholar
• Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol. 2000;35:1628–1637.
   PubMed Web of Science ®Google Scholar
• Anand IS, Latini R, Florea VG, et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation. 2005;112:1428–1434.
   PubMed Web of Science ®Google Scholar
• Di Napoli M, Papa F, Bocola V. C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke. 2001;32:917–924.
   PubMed Web of Science ®Google Scholar
• Di Napoli M, Schwaninger M, Cappelli R, et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke. 2005;36:1316–1329.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767–1772.
   PubMed Web of Science ®Google Scholar
• Kaptoge S, Seshasai SR, Gao P, et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J. 2014;35:578–589.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–1131.
   PubMed Web of Science ®Google Scholar
• Wollert KC, Kempf T, Peter T, et al. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation. 2007;115:962–971.
   PubMed Web of Science ®Google Scholar
• Kempf T, von Haehling S, Peter T, et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol. 2007;50:1054–1060.
   PubMed Web of Science ®Google Scholar
• Anand IS, Kempf T, Rector TS, et al. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation. 2010;122:1387–1395.
   PubMed Web of Science ®Google Scholar
• Hijazi Z, Oldgren J, Lindback J, et al. A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. Eur Heart J. 2018;39:477–485.
   PubMed Web of Science ®Google Scholar
• Januzzi JL, Peacock WF, Maisel AS, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol. 2007;50:607–613.
   PubMed Web of Science ®Google Scholar
• Pascual-Figal DA, Ordonez-Llanos J, Tornel PL, et al. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol. 2009;54:2174–2179.
   PubMed Web of Science ®Google Scholar
• Kohli P, Bonaca MP, Kakkar R, et al. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem. 2012;58:257–266.
   PubMed Web of Science ®Google Scholar
• Jenkins WS, Roger VL, Jaffe AS, et al. Prognostic value of soluble ST2 after myocardial infarction: a community perspective. Am J Med. 2017;130:1112 e9–1112 e15.
   Web of Science ®Google Scholar
• Dieplinger B, Egger M, Haltmayer M, et al. Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the Ludwigshafen risk and cardiovascular health study. Clin Chem. 2014;60:530–540.
   PubMed Web of Science ®Google Scholar
• Pascual-Figal DA, Manzano-Fernandez S, Boronat M, et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail. 2011;13:718–725.
   PubMed Web of Science ®Google Scholar
• Wolcott Z, Batra A, Bevers MB, et al. Soluble ST2 predicts outcome and hemorrhagic transformation after acute stroke. Ann Clin Transl Neurol. 2017;4:553–563.
   PubMed Web of Science ®Google Scholar
• Rudolf JW, Lewandrowski EL, Lewandrowski KB, et al. ST2 predicts mortality and length of stay in a critically Ill noncardiac intensive care unit population. Am J Clin Pathol. 2016;145:203–210.
   PubMed Web of Science ®Google Scholar
• Lok DJ, Van Der Meer P, de la Porte PW, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010;99:323–328.
   PubMed Web of Science ®Google Scholar
• Shah RV, Chen-Tournoux AA, Picard MH, et al. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail. 2010;12:826–832.
   PubMed Web of Science ®Google Scholar
• van Kimmenade RR, Januzzi JL Jr, Ellinor PT, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006;48:1217–1224.
   PubMed Web of Science ®Google Scholar
• de Boer RA, Lok DJ, Jaarsma T, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011;43:60–68.
   PubMed Web of Science ®Google Scholar
• Schonbeck U, Varo N, Libby P, et al. Soluble CD40L and cardiovascular risk in women. Circulation. 2001;104:2266–2268.
   PubMed Web of Science ®Google Scholar
• Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003;348:1104–1111.
   PubMed Web of Science ®Google Scholar
• Varo N, de LJA, Libby P, et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation. 2003;108:1049–1052.
   PubMed Web of Science ®Google Scholar
• Davi G, Tuttolomondo A, Santilli F, et al. CD40 ligand and MCP-1 as predictors of cardiovascular events in diabetic patients with stroke. J Atheroscler Thromb. 2009;16:707–713.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation. 2001;103:491–495.
   PubMed Web of Science ®Google Scholar
• Packard CJ, O'Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000;343:1148–1155.
   PubMed Web of Science ®Google Scholar
• Oei HH, van der Meer IM, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation. 2005;111:570–575.
   PubMed Web of Science ®Google Scholar
• The Lp-PLA2 Studies Collaboration. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010;375:1536–1544.
   PubMed Web of Science ®Google Scholar
• Gerber Y, McConnell JP, Jaffe AS, et al. Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community. Arterioscler Thromb Vasc Biol. 2006;26:2517–2522.
   PubMed Web of Science ®Google Scholar
• Jefferis BJ, Whincup P, Welsh P, et al. Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women. Atherosclerosis. 2010;208:557–563.
   PubMed Web of Science ®Google Scholar
• Welsh P, Whincup PH, Papacosta O, et al. Serum matrix metalloproteinase-9 and coronary heart disease: a prospective study in middle-aged men. QJM. 2008;101:785–791.
   PubMed Web of Science ®Google Scholar
• Wagner DR, Delagardelle C, Ernens I, et al. Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. J Card Fail. 2006;12:66–72.
   PubMed Web of Science ®Google Scholar
• Blankenberg S, Rupprecht HJ, Poirier O, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 2003;107:1579–1585.
   PubMed Web of Science ®Google Scholar
• Morishita T, Uzui H, Mitsuke Y, et al. Association between matrix metalloproteinase-9 and worsening heart failure events in patients with chronic heart failure. ESC Heart Fail. 2017;4:321–330.
   PubMed Web of Science ®Google Scholar
• Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819–823.
   PubMed Web of Science ®Google Scholar
• Jansson AM, Rosjo H, Omland T, et al. Prognostic value of circulating chromogranin A levels in acute coronary syndromes. Eur Heart J. 2008;30:25–32.
   PubMed Web of Science ®Google Scholar
• Ottesen AH, Carlson CR, Louch WE, et al. Glycosylated chromogranin A in heart failure: implications for processing and cardiomyocyte calcium homeostasis. Circ Heart Fail. 2017;10.
   PubMed Web of Science ®Google Scholar
• Ottesen AH, Louch WE, Carlson CR, et al. Secretoneurin is a novel prognostic cardiovascular biomarker associated with cardiomyocyte calcium handling. J Am Coll Cardiol. 2015;65:339–351.
   PubMed Web of Science ®Google Scholar
• Myhre PL, Ottesen AH, Okkonen M, et al. Prognostic value of secretoneurin in patients with acute respiratory failure: data from the FINNALI Study. Clin Chem. 2016;62:1380–1389.
   PubMed Web of Science ®Google Scholar
• Rosjo H, Stridsberg M, Ottesen AH, et al. Prognostic value of secretoneurin in critically Ill patients with infections. Crit Care Med. 2016;44:1882–1890.
   PubMed Web of Science ®Google Scholar
• Rosjo H, Masson S, Caironi P, et al. Prognostic value of secretoneurin in patients with severe sepsis and septic shock: data from the Albumin Italian Outcome Sepsis Study. Crit Care Med. 2018;46:404–410.
   Web of Science ®Google Scholar
• Mohammed AA, Januzzi JL. Clinical applications of highly sensitive troponin assays. Cardiol Rev. 2010;18:12–19.
   PubMed Web of Science ®Google Scholar
• Katus HA, Remppis A, Looser S, et al. Enzyme linked immuno assay of cardiac troponin T for the detection of acute myocardial infarction in patients. J Mol Cell Cardiol. 1989;21:1349–1353.
   PubMed Web of Science ®Google Scholar
• Bodor GS, Porter S, Landt Y, et al. Development of monoclonal antibodies for an assay of cardiac troponin-I and preliminary results in suspected cases of myocardial infarction. Clin Chem. 1992;38:2203–2214.
   PubMed Web of Science ®Google Scholar
• Antman E, Bassand J-P, Klein W, et al. Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36:959–969.
   PubMed Web of Science ®Google Scholar
• Cervellin G, Mattiuzzi C, Bovo C, et al. Diagnostic algorithms for acute coronary syndrome-is one better than another? Ann Transl Med. 2016;4:193.
   PubMed Web of Science ®Google Scholar
• Morrow DA. Clinician's guide to early rule-out strategies with high-sensitivity cardiac troponin. Circulation. 2017;135:1612–1616.
   PubMed Web of Science ®Google Scholar
• Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med. 2009;361:858–867.
   PubMed Web of Science ®Google Scholar
• Zhelev Z, Hyde C, Youngman E, et al. Diagnostic accuracy of single baseline measurement of Elecsys Troponin T high-sensitive assay for diagnosis of acute myocardial infarction in emergency department: systematic review and meta-analysis. BMJ. 2015;350:h15.
   PubMed Web of Science ®Google Scholar
• Body R, Mueller C, Giannitsis E, et al. The use of very low concentrations of high-sensitivity troponin T to rule out acute myocardial infarction using a single blood test. Acad Emerg Med. 2016;23:1004–1013.
   PubMed Web of Science ®Google Scholar
• Pickering JW, Than MP, Cullen L, et al. Rapid rule-out of acute myocardial infarction with a single high-sensitivity cardiac troponin T measurement below the limit of detection: a collaborative meta-analysis. Ann Intern Med. 2017;166:715–724.
   PubMed Web of Science ®Google Scholar
• Shah ASV, Anand A, Strachan FE, et al. High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial. Lancet. 2018. [Epub ahead of print]
   Google Scholar
• Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:267–315.
   PubMed Web of Science ®Google Scholar
• Kavsak PA. External quality assessment testing near the limit of detection for high-sensitivity cardiac troponin assays. Clin Chem. 2018;64:1402–1404.
   PubMed Web of Science ®Google Scholar
• Lyon AW, Kavsak PA, Lyon OA, et al. Simulation models of misclassification error for single thresholds of high-sensitivity cardiac troponin I due to assay bias and imprecision. Clin Chem. 2017;63:585–592.
   PubMed Web of Science ®Google Scholar
• Apple FS, Jaffe AS. Clinical implications of a recent adjustment to the high-sensitivity cardiac troponin T assay: user beware. Clin Chem. 2012;58:1599–1600.
   PubMed Web of Science ®Google Scholar
• Kavsak PA, Worster A, Oliver R, et al. Variability between reagent lots for high-sensitivity cardiac troponin I may affect performance of early rule out strategies. Can J Cardiol. 2018;34:209 e5–209 e6.
   Web of Science ®Google Scholar
• Wu AHB, Christenson RH, Greene DN, et al. Clinical laboratory practice recommendations for the use of cardiac troponin in acute coronary syndrome: expert opinion from the Academy of the American Association for Clinical Chemistry and the Task Force on Clinical Applications of Cardiac Bio-Markers of the International Federation of Clinical Chemistry and Laboratory Medicine. Clin Chem. 2018;64:645–655.
   PubMed Web of Science ®Google Scholar
• Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol. 2006;48:1–11.
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010;304:2503–2512.
   PubMed Web of Science ®Google Scholar
• Gore MO, Seliger SL, Defilippi CR, et al. Age- and sex-dependent upper reference limits for the high-sensitivity cardiac troponin T assay. J Am Coll Cardiol. 2014;63:1441–1448.
   PubMed Web of Science ®Google Scholar
• Everett BM, Cook NR, Magnone MC, et al. Sensitive cardiac troponin T assay and the risk of incident cardiovascular disease in women with and without diabetes mellitus: the Women's Health Study. Circulation. 2011;123:2811–2818.
   PubMed Web of Science ®Google Scholar
• Apple FS, Murakami MM, Pearce LA, et al. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation. 2002;106:2941–2945.
   PubMed Web of Science ®Google Scholar
• Myhre PL, Omland T, Sarvari SI, et al. Cardiac troponin T concentrations, reversible myocardial ischemia, and indices of left ventricular remodeling in patients with suspected stable Angina Pectoris: a DOPPLER-CIP substudy. Clin Chem. 2018;64:1370–1379.
   PubMed Web of Science ®Google Scholar
• Willeit P, Welsh P, Evans JDW, et al. High-sensitivity cardiac troponin concentration and risk of first-ever cardiovascular outcomes in 154,052 participants. J Am Coll Cardiol. 2017;70:558–568.
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care. 2015;38:51–58.
   PubMed Web of Science ®Google Scholar
• Ford I, Shah AS, Zhang R, et al. High-sensitivity cardiac troponin, statin therapy, and risk of coronary heart disease. J Am Coll Cardiol. 2016;68:2719–2728.
   PubMed Web of Science ®Google Scholar
• Young JM, Pickering JW, George PM, et al. Heart Fatty Acid Binding Protein and cardiac troponin: development of an optimal rule-out strategy for acute myocardial infarction. BMC Emerg Med. 2016;16:34.
   PubMed Web of Science ®Google Scholar
• Kavsak PA, Ainsworth C, Arnold DM, et al. The potential role of a turbidimetric heart-type fatty acid-binding protein assay to aid in the interpretation of persistently elevated, non-changing, cardiac troponin I concentrations. Clin Biochem. 2018;58:53–59.
   PubMed Web of Science ®Google Scholar
• Freda BJ, Tang WH, Van Lente F, et al. Cardiac troponins in renal insufficiency: review and clinical implications. J Am Coll Cardiol. 2002;40:2065–2071.
   PubMed Web of Science ®Google Scholar
• Januzzi JL Jr, Filippatos G, Nieminen M, et al. Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section. Eur Heart J. 2012;33:2265–2271.
   PubMed Web of Science ®Google Scholar
• Kavsak PA, Roy C, Malinowski P, et al. Macrocomplexes and discordant high-sensitivity cardiac troponin concentrations. Ann Clin Biochem. 2018;55:500–504.
   PubMed Web of Science ®Google Scholar
• Niizeki T, Takeishi Y, Arimoto T, et al. Combination of heart-type fatty acid binding protein and brain natriuretic peptide can reliably risk stratify patients hospitalized for chronic heart failure. Circ J. 2005;69:922–927.
   PubMed Web of Science ®Google Scholar
• Goto T, Takase H, Toriyama T, et al. Circulating concentrations of cardiac proteins indicate the severity of congestive heart failure. Heart. 2003;89:1303–1307.
   PubMed Web of Science ®Google Scholar
• Schreiber A, Specht B, Pelsers MM, et al. Recombinant human heart-type fatty acid-binding protein as standard in immunochemical assays. Clin Chem Lab Med. 1998;36:283–288.
   PubMed Web of Science ®Google Scholar
• Bathia DP, Carless DR, Viswanathan K, et al. Serum 99th centile values for two heart-type fatty acid binding protein assays. Ann Clin Biochem. 2009;46:464–467.
   PubMed Web of Science ®Google Scholar
• Offer G, Moos C, Starr R. A new protein of the thick filaments of vertebrate skeletal myofibrils. Extractions, purification and characterization. J Mol Biol. 1973;74:653–676.
   PubMed Web of Science ®Google Scholar
• Baker JO, Tyther R, Liebetrau C, et al. Cardiac myosin-binding protein C: a potential early biomarker of myocardial injury. Basic Res Cardiol. 2015;110:23.
   PubMed Web of Science ®Google Scholar
• Marjot J, Liebetrau C, Goodson RJ, et al. The development and application of a high-sensitivity immunoassay for cardiac myosin-binding protein C. Transl Res. 2016;170:17–25 e5.
   PubMed Web of Science ®Google Scholar
• Kaier TE, Anand A, Shah AS, et al. Temporal relationship between cardiac myosin-binding protein C and cardiac troponin I in type 1 myocardial infarction. Clin Chem. 2016;62:1153–1155.
   PubMed Web of Science ®Google Scholar
• Kaier TE, Twerenbold R, Puelacher C, et al. Direct comparison of cardiac myosin-binding protein C with cardiac troponins for the early diagnosis of acute myocardial infarction. Circulation. 2017;136:1495–1508.
   PubMedGoogle Scholar
• Anand A, Chin C, Shah ASV, et al. Cardiac myosin-binding protein C is a novel marker of myocardial injury and fibrosis in aortic stenosis. Heart. 2018;104:1101–1108.
   PubMed Web of Science ®Google Scholar
• de Bold AJ, Borenstein HB, Veress AT, et al. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981;28:89–94.
   PubMed Web of Science ®Google Scholar
• Yan W, Wu F, Morser J, et al. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci U S A. 2000;97:8525–8529.
   PubMed Web of Science ®Google Scholar
• Buckley MG, Marcus NJ, Yacoub MH. Cardiac peptide stability, aprotinin and room temperature: importance for assessing cardiac function in clinical practice. Clin Sci. 1999;97:689–695.
   PubMed Web of Science ®Google Scholar
• Ala-Kopsala M, Magga J, Peuhkurinen K, et al. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. Clin Chem. 2004;50:1576–1588.
   PubMed Web of Science ®Google Scholar
• von Haehling S, Jankowska EA, Morgenthaler NG, et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J Am Coll Cardiol. 2007;50:1973–1980.
   PubMed Web of Science ®Google Scholar
• Masson S, Latini R, Carbonieri E, et al. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail. 2010;12:338–347.
   PubMed Web of Science ®Google Scholar
• Tzikas S, Keller T, Ojeda FM, et al. MR-proANP and MR-proADM for risk stratification of patients with acute chest pain. Heart. 2013;99:388–395.
   PubMed Web of Science ®Google Scholar
• Omland T, Aarsland T, Aakvaag A, et al. Prognostic value of plasma atrial natriuretic factor, norepinephrine and epinephrine in acute myocardial infarction. Am J Cardiol. 1993;72:255–259.
   PubMed Web of Science ®Google Scholar
• de Lemos JA, McGuire DK, Drazner MH, B-type natriuretic peptide in cardiovascular disease. Lancet. 2003;362:316–322.
   PubMed Web of Science ®Google Scholar
• Rosjo H, Dahl MB, Jorgensen M, et al. Influence of glycosylation on diagnostic and prognostic accuracy of N-terminal pro-B-type natriuretic peptide in acute dyspnea: data from the Akershus Cardiac Examination 2 Study. Clin Chem. 2015;61:1087–1097.
   PubMed Web of Science ®Google Scholar
• Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008;358:2148–2159.
   PubMed Web of Science ®Google Scholar
• Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27:330–337.
   PubMed Web of Science ®Google Scholar
• Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631–2639.
   PubMed Web of Science ®Google Scholar
• deFilippi CR, Christenson RH, Gottdiener JS, et al. Dynamic cardiovascular risk assessment in elderly people. The role of repeated N-terminal pro-B-type natriuretic peptide testing. J Am Coll Cardiol. 2010;55:441–450.
   PubMed Web of Science ®Google Scholar
• Masson S, Latini R, Anand IS, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem. 2006;52:1528–1538.
   PubMed Web of Science ®Google Scholar
• Lainchbury JG, Troughton RW, Strangman KM, et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol. 2009;55:53–60.
   PubMed Web of Science ®Google Scholar
• Persson H, Erntell H, Eriksson B, et al. Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure–SIGNAL-HF (Swedish Intervention study–Guidelines and NT-proBNP AnaLysis in Heart Failure). Eur J Heart Fail. 2010;12:1300–1308.
   PubMed Web of Science ®Google Scholar
• Felker GM, Ahmad T, Anstrom KJ, et al. Rationale and design of the GUIDE-IT study: guiding evidence based therapy using biomarker intensified treatment in heart failure. JACC Heart Fail. 2014;2:457–465.
   PubMed Web of Science ®Google Scholar
• Felker GM, Anstrom KJ, Adams KF, et al. Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2017;318:713–720.
   PubMed Web of Science ®Google Scholar
• Omland T, Bonarjee VV, Nilsen DW, et al. Prognostic significance of N-terminal pro-atrial natriuretic factor (1-98) in acute myocardial infarction: comparison with atrial natriuretic factor (99–126) and clinical evaluation. Br Heart J. 1993;70:409–414.
   PubMedGoogle Scholar
• Omland T, de Lemos JA, Morrow DA, et al. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol. 2002;89:463–465.
   PubMed Web of Science ®Google Scholar
• Omland T, Persson A, Ng L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation. 2002;106:2913–2918.
   PubMed Web of Science ®Google Scholar
• Lam CS, Cheng S, Choong K, et al. Influence of sex and hormone status on circulating natriuretic peptides. J Am Coll Cardiol. 2011;58:618–626.
   PubMed Web of Science ®Google Scholar
• Gupta DK, de Lemos JA, Ayers CR, et al. Racial differences in natriuretic peptide levels: the Dallas Heart Study. JACC Heart Fail. 2015;3:513–519.
   PubMed Web of Science ®Google Scholar
• Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109:594–600.
   PubMed Web of Science ®Google Scholar
• Kitamura K, Kangawa K, Kawamoto M, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun. 1993;192:553–560.
   PubMed Web of Science ®Google Scholar
• Nishio K, Akai Y, Murao Y, et al. Increased plasma concentrations of adrenomedullin correlate with relaxation of vascular tone in patients with septic shock. Crit Care Med. 1997;25:953–957.
   PubMed Web of Science ®Google Scholar
• Ishimitsu T, Nishikimi T, Saito Y, et al. Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest. 1994;94:2158–2161.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Wolbers M, Christ-Crain M, et al. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit Care. 2010;14:R106.
   PubMed Web of Science ®Google Scholar
• Struck J, Tao C, Morgenthaler NG, et al. Identification of an adrenomedullin precursor fragment in plasma of sepsis patients. Peptides. 2004;25:1369–1372.
   PubMed Web of Science ®Google Scholar
• Smith JG, Newton-Cheh C, Hedblad B, et al. Distribution and correlates of midregional proadrenomedullin in the general population. Clin Chem. 2009;55:1593–1595.
   PubMed Web of Science ®Google Scholar
• Eggers KM, Venge P, Lindahl B, et al. Associations of mid-regional pro-adrenomedullin levels to cardiovascular and metabolic abnormalities, and mortality in an elderly population from the community. Int J Cardiol. 2013;168:3537–3542.
   PubMed Web of Science ®Google Scholar
• Krintus M, Kozinski M, Braga F, et al. Plasma midregional proadrenomedullin (MR-proADM) concentrations and their biological determinants in a reference population. Clin Chem Lab Med. 2018;56:1161–1168.
   PubMed Web of Science ®Google Scholar
• Pervez MO, Lyngbakken MN, Myhre PL, et al. Mid-regional pro-adrenomedullin in patients with acute dyspnea: data from the Akershus Cardiac Examination (ACE) 2 study. Clin Biochem. 2017;50:394–400.
   PubMed Web of Science ®Google Scholar
• Kitamura K, Kangawa K, Eto T. Adrenomedullin and PAMP: discovery, structures, and cardiovascular functions. Microsc Res Technol. 2002;57:3–13.
   PubMed Web of Science ®Google Scholar
• Morgenthaler NG, Struck J, Alonso C, et al. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem. 2005;51:1823–1829.
   PubMed Web of Science ®Google Scholar
• Christ-Crain M, Fenske W. Copeptin in the diagnosis of vasopressin-dependent disorders of fluid homeostasis. Nat Rev Endocrinol. 2016;12:168–176.
   PubMed Web of Science ®Google Scholar
• Muller B, Morgenthaler N, Stolz D, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest. 2007;37:145–152.
   PubMed Web of Science ®Google Scholar
• Blankenberg S, McQueen MJ, Smieja M, et al. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 2006;114:201–208.
   PubMed Web of Science ®Google Scholar
• Oluleye OW, Folsom AR, Nambi V, et al. Troponin T, B-type natriuretic peptide, C-reactive protein, and cause-specific mortality. Ann Epidemiol. 2013;23:66–73.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
   PubMed Web of Science ®Google Scholar
• Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37:2315–2381.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cushman M, Stampfer MJ, et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998;97:425–428.
   PubMed Web of Science ®Google Scholar
• Ridker PM, MacFadyen JG, Everett BM, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391:319–328.
   PubMed Web of Science ®Google Scholar
• James SK, Armstrong P, Barnathan E, et al. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol. 2003;41:916–924.
   PubMed Web of Science ®Google Scholar
• Kavsak PA, Ko DT, Newman AM, et al. Risk stratification for heart failure and death in an acute coronary syndrome population using inflammatory cytokines and N-terminal pro-brain natriuretic peptide. Clin Chem. 2007;53:2112–2118.
   PubMed Web of Science ®Google Scholar
• Kavsak PA, MacRae AR, Newman AM, et al. Elevated C-reactive protein in acute coronary syndrome presentation is an independent predictor of long-term mortality and heart failure. Clin Biochem. 2007;40:326–329.
   PubMed Web of Science ®Google Scholar
• Suleiman M, Khatib R, Agmon Y, et al. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J Am Coll Cardiol. 2006;47:962–968.
   PubMed Web of Science ®Google Scholar
• Zamani P, Schwartz GG, Olsson AG, et al. Inflammatory biomarkers, death, and recurrent nonfatal coronary events after an acute coronary syndrome in the MIRACL study. J Am Heart Assoc. 2013;2:e003103.
   PubMed Web of Science ®Google Scholar
• Wensley F, Gao P, Burgess S, et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ. 2011;342:d548.
   PubMed Web of Science ®Google Scholar
• Lindmark E, Diderholm E, Wallentin L, et al. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA. 2001;286:2107–2113.
   PubMed Web of Science ®Google Scholar
• Tan J, Hua Q, Gao J, et al. Clinical implications of elevated serum interleukin-6, soluble CD40 ligand, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in patients with acute ST-segment elevation myocardial infarction. Clin Cardiol. 2008;31:413–418.
   PubMed Web of Science ®Google Scholar
• Swerdlow DI, Holmes MV, Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379:1214–1224.
   PubMed Web of Science ®Google Scholar
• Bottner M, Laaff M, Schechinger B, et al. Characterization of the rat, mouse, and human genes of growth/differentiation factor-15/macrophage inhibiting cytokine-1 (GDF-15/MIC-1). Gene. 1999;237:105–111.
   PubMed Web of Science ®Google Scholar
• Vila G, Riedl M, Anderwald C, et al. The relationship between insulin resistance and the cardiovascular biomarker growth differentiation factor-15 in obese patients. Clin Chem. 2011;57:309–316.
   PubMed Web of Science ®Google Scholar
• Farhan S, Freynhofer MK, Brozovic I, et al. Determinants of growth differentiation factor 15 in patients with stable and acute coronary artery disease. A prospective observational study. Cardiovasc Diabetol. 2016;15:60.
   PubMed Web of Science ®Google Scholar
• Kempf T, Eden M, Strelau J, et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res. 2006;98:351–360.
   PubMed Web of Science ®Google Scholar
• Xu J, Kimball TR, Lorenz JN, et al. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res. 2006;98:342–350.
   PubMed Web of Science ®Google Scholar
• Kempf T, Zarbock A, Widera C, et al. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med. 2011;17:581–588.
   PubMed Web of Science ®Google Scholar
• Mueller T, Leitner I, Egger M, et al. Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases. Clin Chim Acta. 2015;445:155–160.
   PubMed Web of Science ®Google Scholar
• Schaub N, Reichlin T, Twerenbold R, et al. Growth differentiation factor-15 in the early diagnosis and risk stratification of patients with acute chest pain. Clin Chem. 2012;58:441–449.
   PubMed Web of Science ®Google Scholar
• Rohatgi A, Patel P, Das SR, et al. Association of growth differentiation factor-15 with coronary atherosclerosis and mortality in a young, multiethnic population: observations from the Dallas Heart Study. Clin Chem. 2012;58:172–182.
   PubMed Web of Science ®Google Scholar
• Wang TJ, Wollert KC, Larson MG, et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation. 2012;126:1596–1604.
   PubMed Web of Science ®Google Scholar
• Brown DA, Breit SN, Buring J, et al. Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case–control study. Lancet. 2002;359:2159–2163.
   PubMed Web of Science ®Google Scholar
• Lind L, Wallentin L, Kempf T, et al. Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Eur Heart J. 2009;30:2346–2353.
   PubMed Web of Science ®Google Scholar
• Hagstrom E, James SK, Bertilsson M, et al. Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. Eur Heart J. 2016;37:1325–1333.
   PubMed Web of Science ®Google Scholar
• Chan MM, Santhanakrishnan R, Chong JP, et al. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail. 2016;18:81–88.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Hijazi Z, Andersson U, et al. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014;130:1847–1858.
   PubMed Web of Science ®Google Scholar
• Hijazi Z, Lindback J, Alexander JH, et al. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016;37:1582–1590.
   PubMed Web of Science ®Google Scholar
• Hijazi Z, Oldgren J, Lindback J, et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016;387:2302–2311.
   PubMed Web of Science ®Google Scholar
• Hijazi Z, Oldgren J, Andersson U, et al. Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Am Heart J. 2017;190:94–103.
   PubMed Web of Science ®Google Scholar
• Tominaga S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett. 1989;258:301–304.
   PubMed Web of Science ®Google Scholar
• Klemenz R, Hoffmann S, Werenskiold AK. Serum- and oncoprotein-mediated induction of a gene with sequence similarity to the gene encoding carcinoembryonic antigen. Proc Natl Acad Sci USA. 1989;86:5708–5712.
   PubMed Web of Science ®Google Scholar
• Werenskiold AK, Hoffmann S, Klemenz R. Induction of a mitogen-responsive gene after expression of the Ha-ras oncogene in NIH 3T3 fibroblasts. Mol Cell Biol. 1989;9:5207–5214.
   PubMed Web of Science ®Google Scholar
• Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117:1538–1549.
   PubMed Web of Science ®Google Scholar
• Ky B, French B, Levy WC, et al. Multiple biomarkers for risk prediction in chronic heart failure. Circ Heart Fail. 2012;5:183–190.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Morrow DA, Higgins LJ, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008;117:1936–1944.
   PubMed Web of Science ®Google Scholar
• Boisot S, Beede J, Isakson S, et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail. 2008;14:732–738.
   PubMed Web of Science ®Google Scholar
• Miller WL, Saenger AK, Grill DE, et al. Prognostic value of serial measurements of soluble suppression of tumorigenicity 2 and galectin-3 in ambulatory patients with chronic heart failure. J Card Fail. 2016;22:249–255.
   PubMed Web of Science ®Google Scholar
• Gaggin HK, Motiwala S, Bhardwaj A, et al. Soluble concentrations of the interleukin receptor family member ST2 and beta-blocker therapy in chronic heart failure. Circ Heart Fail. 2013;6:1206–1213.
   PubMed Web of Science ®Google Scholar
• Weir RA, Miller AM, Murphy GE, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol. 2010;55:243–250.
   PubMed Web of Science ®Google Scholar
• Writing Committee Members, Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:e240–e327.
   PubMed Web of Science ®Google Scholar
• Bayes-Genis A, de Antonio M, Vila J, et al. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J Am Coll Cardiol. 2014;63:158–166.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37:2129–2200.
   PubMed Web of Science ®Google Scholar
• Cooper DN. Galectinomics: finding themes in complexity. Biochim Biophys Acta. 2002;1572:209–231.
   PubMed Web of Science ®Google Scholar
• Sano H, Hsu DK, Apgar JR, et al. Critical role of galectin-3 in phagocytosis by macrophages. J Clin Invest. 2003;112:389–397.
   PubMed Web of Science ®Google Scholar
• Funasaka T, Raz A, Nangia-Makker P. Galectin-3 in angiogenesis and metastasis. Glycobiology. 2014;24:886–891.
   PubMed Web of Science ®Google Scholar
• Yang RY, Hsu DK, Liu FT. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci U S A. 1996;93:6737–6742.
   PubMed Web of Science ®Google Scholar
• Dumic J, Dabelic S, Flogel M. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006;1760:616–635.
   PubMed Web of Science ®Google Scholar
• Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110:3121–3128.
   PubMed Web of Science ®Google Scholar
• Wu AH, Wians F, Jaffe A. Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results. Am Heart J. 2013;165:995–999.
   PubMed Web of Science ®Google Scholar
• Yang RY, Rabinovich GA, Liu FT. Galectins: structure, function and therapeutic potential. Expert Rev Mol Med. 2008;10:e17.
   PubMedGoogle Scholar
• Milting H, Ellinghaus P, Seewald M, et al. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant. 2008;27:589–596.
   PubMed Web of Science ®Google Scholar
• Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci. 2001;58:4–43.
   PubMed Web of Science ®Google Scholar
• Lutgens E, Gorelik L, Daemen MJ, et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med. 1999;5:1313–1316.
   PubMed Web of Science ®Google Scholar
• Nannizzi-Alaimo L, Alves VL, Phillips DR. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation. 2003;107:1123–1128.
   PubMed Web of Science ®Google Scholar
• Rosen SD, Bertozzi CR. The selectins and their ligands. Curr Opin Cell Biol. 1994;6:663–673.
   PubMed Web of Science ®Google Scholar
• Johnson-Tidey RR, McGregor JL, Taylor PR, et al. Increase in the adhesion molecule P-selectin in endothelium overlying atherosclerotic plaques. Coexpression with intercellular adhesion molecule-1. Am J Pathol. 1994;144:952–961.
   PubMed Web of Science ®Google Scholar
• Dong ZM, Brown AA, Wagner DD. Prominent role of P-selectin in the development of advanced atherosclerosis in ApoE-deficient mice. Circulation. 2000;101:2290–2295.
   PubMed Web of Science ®Google Scholar
• Blann AD, McCollum CN. Increased soluble P-selectin in peripheral artery disease: a new marker for the progression of atherosclerosis. Thromb Haemost. 1998;80:1031–1032.
   PubMed Web of Science ®Google Scholar
• Blann AD, Faragher EB, McCollum CN. Increased soluble P-selectin following myocardial infarction: a new marker for the progression of atherosclerosis. Blood Coagul Fibrinolysis. 1997;8:383–390.
   PubMed Web of Science ®Google Scholar
• Caslake MJ, Packard CJ, Suckling KE, et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis. 2000;150:413–419.
   PubMed Web of Science ®Google Scholar
• Stability Investigators, White HD, Held C, Stewart R, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014;370:1702–1711.
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Braunwald E, White HD, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA. 2014;312:1006–1015.
   PubMed Web of Science ®Google Scholar
• Sluijter JP, Pulskens WP, Schoneveld AH, et al. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke. 2006;37:235–239.
   PubMed Web of Science ®Google Scholar
• Yabluchanskiy A, Ma Y, Iyer RP, et al. Matrix metalloproteinase-9: many shades of function in cardiovascular disease. Physiology. 2013;28:391–403.
   PubMed Web of Science ®Google Scholar
• Ramos-Fernandez M, Bellolio MF, Stead LG. Matrix metalloproteinase-9 as a marker for acute ischemic stroke: a systematic review. J Stroke Cerebrovasc Dis. 2011;20:47–54.
   PubMed Web of Science ®Google Scholar
• Ducharme A, Frantz S, Aikawa M, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest. 2000;106:55–62.
   PubMed Web of Science ®Google Scholar
• Lindsey ML, Gannon J, Aikawa M, et al. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation. 2002;105:753–758.
   PubMed Web of Science ®Google Scholar
• Hayashidani S, Tsutsui H, Shiomi T, et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2002;105:868–873.
   PubMed Web of Science ®Google Scholar
• Latini R, Masson S, Anand I, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J. 2004;25:292–299.
   PubMed Web of Science ®Google Scholar
• Dimsdale JE, Ziegler MG. What do plasma and urinary measures of catecholamines tell us about human response to stressors? Circulation. 1991;83:II36–II42.
   PubMed Web of Science ®Google Scholar
• Bartolomucci A, Possenti R, Mahata SK, et al. The extended granin family: structure, function, and biomedical implications. Endocr Rev. 2011;32:755–797.
   PubMed Web of Science ®Google Scholar
• Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med. 2003;348:1134–1149.
   PubMed Web of Science ®Google Scholar
• Helle KB. The granin family of uniquely acidic proteins of the diffuse neuroendocrine system: comparative and functional aspects. Biol Rev Camb Philos Soc. 2004;79:769–794.
   PubMed Web of Science ®Google Scholar
• O'Connor DT, Deftos LJ. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med. 1986;314:1145–1151.
   PubMed Web of Science ®Google Scholar
• Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42:557–577.
   PubMed Web of Science ®Google Scholar
• Dimsdale JE, O'Connor DT, Ziegler M, et al. Chromogranin A correlates with norepinephrine release rate. Life Sci. 1992;51:519–525.
   PubMed Web of Science ®Google Scholar
• Rosjo H, Masson S, Latini R, et al. Prognostic value of chromogranin A in chronic heart failure: data from the GISSI-Heart Failure trial. Eur J Heart Fail. 2010;12:549–556.
   PubMed Web of Science ®Google Scholar
• Stridsberg M, Eriksson B, Oberg K, et al. A comparison between three commercial kits for chromogranin A measurements. J Endocrinol. 2003;177:337–341.
   PubMed Web of Science ®Google Scholar
• O'Connor DT, Pandlan MR, Carlton E, et al. Rapid radioimmunoassay of circulating chromogranin A: in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure. Clin Chem. 1989;35:1631–1637.
   PubMed Web of Science ®Google Scholar
• Fischer-Colbrie R, Kirchmair R, Kahler CM, et al. Secretoneurin: a new player in angiogenesis and chemotaxis linking nerves, blood vessels and the immune system. CPPS. 2005;6:373–385.
   Google Scholar
• Leitner B, Schneitler C, Klocker H, et al. Formation and sequence analysis of secretoneurin, a neuropeptide derived from secretogranin II, in mammalian, bird, reptile, amphibian and fish brains. Neurosci Lett. 1998;248:105–108.
   PubMed Web of Science ®Google Scholar
• Anderson ME, Brown JH, Bers DM. CaMKII in myocardial hypertrophy and heart failure. J Mol Cell Cardiol. 2011;51:468–473.
   PubMed Web of Science ®Google Scholar
• Singh MV, Kapoun A, Higgins L, et al. Ca2+/calmodulin-dependent kinase II triggers cell membrane injury by inducing complement factor B gene expression in the mouse heart. J Clin Invest. 2009;119:986–996.
   PubMed Web of Science ®Google Scholar
• Rosjo H, Stridsberg M, Florholmen G, et al. Secretogranin II; a protein increased in the myocardium and circulation in heart failure with cardioprotective properties. PLoS One. 2012;7:e37401.
   PubMed Web of Science ®Google Scholar
• Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary Artery Disease Investigators. Lancet. 1999;354:708–715.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879–1887.
   PubMed Web of Science ®Google Scholar
• Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet. 2002;360:743–751.
   PubMed Web of Science ®Google Scholar
• Januzzi JL, Troughton R. Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management. Circulation. 2013;127:500–508.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Shimizu W, Albert CM. The spectrum of epidemiology underlying sudden cardiac death. Circ Res. 2015;116:1887–1906.
   PubMed Web of Science ®Google Scholar
• Korngold EC, Januzzi JL, Gantzer ML, et al. Amino-terminal pro-B-type natriuretic peptide and high-sensitivity C-reactive protein as predictors of sudden cardiac death among women. Circulation. 2009;119:2868–2876.
   PubMed Web of Science ®Google Scholar
• Hussein AA, Gottdiener JS, Bartz TM, et al. Cardiomyocyte injury assessed by a highly sensitive troponin assay and sudden cardiac death in the community: the Cardiovascular Health Study. J Am Coll Cardiol. 2013;62:2112–2120.
   PubMed Web of Science ®Google Scholar
• Myhre PL, Tiainen M, Pettila V, et al. NT-proBNP in patients with out-of-hospital cardiac arrest: results from the FINNRESUSCI Study. Resuscitation. 2016;104:12–18.
   PubMed Web of Science ®Google Scholar
• Skali H, Gerwien R, Meyer TE, et al. Soluble ST2 and risk of arrhythmias, heart failure, or death in patients with mildly symptomatic heart failure: results from MADIT-CRT. J Cardiovasc Trans Res. 2016;9:421–428.
   PubMed Web of Science ®Google Scholar
• Baumeister P, Quinn TA. Altered calcium handling and ventricular arrhythmias in acute ischemia. Clin Med Insights Cardiol. 2016;10:61–69.
   PubMed Web of Science ®Google Scholar
• Akosah KO, Schaper A, Cogbill C, et al. Preventing myocardial infarction in the young adult in the first place: how do the National Cholesterol Education Panel III guidelines perform? J Am Coll Cardiol. 2003;41:1475–1479.
   PubMed Web of Science ®Google Scholar
• Singh A, Collins BL, Gupta A, et al. Cardiovascular risk and statin eligibility of young adults after an MI: partners YOUNG-MI Registry. J Am Coll Cardiol. 2018;71:292–302.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297:611–619.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Paynter NP, Rifai N, et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. 2008;118:2243–2251.
   PubMed Web of Science ®Google Scholar
• Blankenberg S, Salomaa V, Makarova N, et al. Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium. Eur Heart J. 2016;37:2428–2437.
   PubMed Web of Science ®Google Scholar
• Lyngbakken MN, Skranes JB, de Lemos JA, et al. Impact of smoking on circulating cardiac troponin I concentrations and cardiovascular events in the general population: the HUNT Study (Nord-Trondelag Health Study). Circulation. 2016;134:1962–1972.
   PubMed Web of Science ®Google Scholar
• Lewis JR, Lim WH, Wong G, et al. Association between high-sensitivity cardiac troponin I and cardiac events in elderly women. J Am Heart Assoc. 2017;6.
   Web of Science ®Google Scholar
• Akintoye E, Briasoulis A, Afonso L. Biochemical risk markers and 10-year incidence of atherosclerotic cardiovascular disease: independent predictors, improvement in pooled cohort equation, and risk reclassification. Am Heart J. 2017;193:95–103.
   PubMed Web of Science ®Google Scholar
• Hochholzer W, Reichlin T, Twerenbold R, et al. Incremental value of high-sensitivity cardiac troponin T for risk prediction in patients with suspected acute myocardial infarction. Clin Chem. 2011;57:1318–1326.
   PubMed Web of Science ®Google Scholar
• Widera C, Pencina MJ, Bobadilla M, et al. Incremental prognostic value of biomarkers beyond the GRACE (Global Registry of Acute Coronary Events) score and high-sensitivity cardiac troponin T in non-ST-elevation acute coronary syndrome. Clin Chem. 2013;59:1497–1505.
   PubMed Web of Science ®Google Scholar
• Klingenberg R, Aghlmandi S, Raber L, et al. Improved risk stratification of patients with acute coronary syndromes using a combination of hsTnT, NT-proBNP and hsCRP with the GRACE score. Eur Heart J Acute Cardiovasc Care. 2018;7:129–138.
   PubMed Web of Science ®Google Scholar
• Mishra RK, Beatty AL, Jaganath R, et al. B-type natriuretic peptides for the prediction of cardiovascular events in patients with stable coronary heart disease: the Heart and Soul Study. J Am Heart Assoc. 2014;3:e000907.
   PubMed Web of Science ®Google Scholar
• Daniels LB, Clopton P, deFilippi CR, et al. Serial measurement of N-terminal pro-B-type natriuretic peptide and cardiac troponin T for cardiovascular disease risk assessment in the Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J. 2015;170:1170–1183.
   PubMed Web of Science ®Google Scholar
• Hijazi Z, Wallentin L, Siegbahn A, et al. Terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for. The Prevention of Stroke in Subjects with Atrial Fibrillation). J Am Coll Cardiol. 2013;61:2274–2284.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Koeda Y, Tanaka F, et al. Plasma B-type natriuretic peptide as a predictor of cardiovascular events in subjects with atrial fibrillation: a community-based study. PLoS One. 2013;8:e81243.
   PubMed Web of Science ®Google Scholar
• Khan SQ, Narayan H, Ng KH, et al. N-terminal pro-B-type natriuretic peptide complements the GRACE risk score in predicting early and late mortality following acute coronary syndrome. Clin Sci. 2009;117:31–39.
   PubMedGoogle Scholar
• Garcia-Alvarez A, Regueiro A, Hernandez J, et al. Additional value of B-type natriuretic peptide on discrimination of patients at risk for mortality after a non-ST-segment elevation acute coronary syndrome. Eur Heart J Acute Cardiovasc Care. 2014;3:132–140.
   PubMedGoogle Scholar
• Wilson PW, Pencina M, Jacques P, et al. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes. 2008;1:92–97.
   PubMed Web of Science ®Google Scholar
• Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA. 2012;308:788–795.
   PubMed Web of Science ®Google Scholar
• Lyngbaek S, Marott JL, Sehestedt T, et al. Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score. Int J Cardiol. 2013;167:2904–2911.
   PubMed Web of Science ®Google Scholar
• Mohlenkamp S, Lehmann N, Moebus S, et al. Quantification of coronary atherosclerosis and inflammation to predict coronary events and all-cause mortality. J Am Coll Cardiol. 2011;57:1455–1464.
   PubMed Web of Science ®Google Scholar
• Gerber Y, Weston SA, Enriquez-Sarano M, et al. Contemporary risk stratification after myocardial infarction in the community: performance of scores and incremental value of soluble suppression of tumorigenicity-2. J Am Heart Assoc. 2017;6.
   PubMed Web of Science ®Google Scholar
• Shlipak MG, Fried LF, Cushman M, et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA. 2005;293:1737–1745.
   PubMed Web of Science ®Google Scholar
• Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358:2107–2116.
   PubMed Web of Science ®Google Scholar
• Richter B, Koller L, Hohensinner PJ, et al. A multi-biomarker risk score improves prediction of long-term mortality in patients with advanced heart failure. Int J Cardiol. 2013;168:1251–1257.
   PubMed Web of Science ®Google Scholar
• Pikula A, Beiser AS, DeCarli C, et al. Multiple biomarkers and risk of clinical and subclinical vascular brain injury: the Framingham Offspring Study. Circulation. 2012;125:2100–2107.
   PubMed Web of Science ®Google Scholar
• Lindholm D, Lindback J, Armstrong PW, et al. Biomarker-based risk model to predict cardiovascular mortality in patients with stable coronary disease. J Am Coll Cardiol. 2017;70:813–826.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.
   PubMed Web of Science ®Google Scholar